tics, tourette, behaviour therapy, exposure and response prevention and habit reversal, risperidone, gedragstherapie, risperidon,
Conditions
Interventions
Behaviour therapy versus medication (risperidone). Both are given during 12 weeks.
Sponsors
HSK group, Arnhem
HagaHospital, The Hague
Academic Anxiety Centre Altrecht, Utrecht
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients have to meet DSM-IV criteria for GTS or CTD; 2. Both children and adults are included, ranging from 6 to 65 years of age; 3. Written informed consent by patients, as well as from their parents in case of children (<16) is necessary to participate in the study.
Exclusion criteria
Exclusion criteria: 1. Severe major depression, psychosis, addiction, mental deficiency; 2. A known cardiovascular disease, family history of QT prolongation, bradycardia, other medication known to prolong QT interval; 3. Inability to read/speak Dutch; 4. Patients need to be free of specific tic medication (antipsychotics) for at least four weeks prior to entering the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measure is the Dutch version of the Yale Global Tic Severity Scale (YGTSS). | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome measures include tic frequency at home and at the institute after 12 weeks, and tic severity and frequency at home and at the institute after 6 and 12 months (follow-up). General assessment of functioning and quality of life, severity of premonitory sensations, severity of comorbidity and side effects will be measured as well, as are effects during half way of treatment (after 6 weeks). Finally, tic suppressibility during a stressfull task is measured, as well as rates and reasons of dropout. | — |
Contacts
Public ContactJolande Griendt, van de
Oude Oeverstraat 120
Outcome results
None listed